Uptake and efflux of two anthracyclines, idarubicin (IDA) and daunorubicin (DNR), was studied in childhood acute leukemia samples. A comparison of IDA and DNR transport phenomena in relation to drug cytotoxicity and expression of P-glycoprotein (PGP) was made. Intracellular content of IDA/DNR was determined by flow cytometry using the fluorescent properties of the drugs. In vitro drug cytotoxicity was Vol. 49 No.
measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
assay. PGP expression was analysed by flow cytometry. The uptake and efflux rates were non-significantly higher for IDA than DNR. There were no differences between three types of leukemia with respect to drug content during accumulation and retention. After correction for the cell volume, intracellular concentration of both drugs in each moment of uptake and efflux was significantly lower in relapsed ALL and AML samples in comparison with initial ALL cells. Efflux, but not uptake, of both drugs was inversely correlated with PGP expression and IDA, but not DNR, cytotoxicity. The cytotoxicity was correlated with drug accumulation for both drugs and with drug retention for IDA. In conclusion, it seems that (1) intracellular content was related to the lipophilic properties of the drugs rather than to the type of leukemia, (2) decreased intracellular concentration of both drugs might have an impact on compromised therapy results in AML and relapsed ALL children, (3) IDA presents higher cytotoxicity, which possibly might be decreased by the presence of PGP. These results might have a practical impact on the rational design of new chemotherapy protocols.
Leukemia is the most common childhood malignancy. Acute lymphoblastic leukemia (ALL) is the predominant form (85%) and acute myeloblastic leukemia (AML) is a relatively uncommon disease (10-15%). With current protocols, 70-80% of children with ALL, and only 30-50% with AML can be cured [1] . Drug resistance is related to relapse of leukemia, but the underlying mechanisms are still poorly understood. Anthracyclines ( Fig. 1 ) are among the drugs used in both types of acute leukemia. Idarubicin (IDA) is a relatively new antitumor anthracycline drug and is thought to be more active and less cardiotoxic than daunorubicin (DNR) [2] . Resistance to anthracyclines may compromise therapy results. The resistance may be caused by reduced intracellular drug levels due to its sequestration by multidrug resistance proteins or detoxification by glutathione and its S-transferases, a reduced amount of active intracellular drug target, such as topoisomerase II, and resistance to apoptosis or its protein disregulation [3] . Anthracyclines enter the cell by passive diffusion, most likely in an unchanged form [4, 5] . So far most information about anthracycline resistance was obtained from in vitro studies on tumor cell lines. There is only one study on childhood acute leukemia, reporting a relationship between intracellular DNR concentration, expression of resistance proteins and DNR cytotoxicity in ALL [6] . It shows that intracellular DNR concentration and the expression of Lung-Resistance-Protein (MVP/LRP), but not P-glycoprotein (PGP), may contribute to DNR resistance in childhood ALL. So far there are no reports available showing whether intracellular IDA content is related to cellular drug resistance and multi-drug resistance proteins expression in childhood leukemia. Moreover, it is unknown what differences in intracellular anthracycline levels occur between ALL and 
MATERIALS AND METHODS
Leukemic cell samples. Samples of leukemic cells of 61 children aged 0.5-18 yrs (median 8 yrs), including 34 with ALL de novo (iALL, group A), 13 relapsed ALL (rALL, group B) and 14 de novo AML (iAML, group C), were analysed. Only fresh peripheral blood (PB) or bone marrow (BM) samples taken at the moment of diagnosis or relapse were analysed. Cells were isolated by centrifugation on Ficoll gradient at 480´g for 20 min at room temperature, washed twice and resuspended in RPMI-1640 (Sigma, St. Louis, MO, U.S.A.) with 20% fetal calf serum (FCS, Gibco BRL, Life Technologies, Germany), 2 mM L-glutamine, 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml sodium selenite (all from Sigma) and antibiotics. All samples presented at least 95% cell viability (determined morphologically by trypan blue exclusion assay) and contained at least 80% of leukemic cells, as calculated on cytospin slides stained with the May-Grunwald-Giemsa method. The concentration of leukemic cells was adjusted to 2´10 6 /ml.
Drugs. Daunorubicin (Cerubidine; Rhone Poulenc Rorer, Amstelveen, The Netherlands) and idarubicin (Zavedos; Pharmacia Farmitalia Oncology, Italy) were used for the study. Drug accumulation and retention. Leukemic cells at a concentration of 0.5´10 6 cells/ml were incubated with 10 mg/ml of respective drug in humidified air containing 5% CO 2 at 37°C. Samples of cells were analysed in 1 h intervals. Accumulation of DNR/IDA was determined at certain time points during continuous exposure to DNR/IDA. To study the retention, cells were first loaded with 10 mg/ml DNR/IDA for 1 h at 37°C. In order to start the efflux, cells were washed in ice-cold phosphate-buffered saline (PBS) and resuspended in a pre-warmed drug-free medium. The retained amount of DNR/IDA was determined at several time points, including the start of efflux (t = 0). Each aliquot (100 ml) was washed immediately in ice-cold PBS and then intracellular DNR/IDA fluorescence (FL) was measured by flow cytometry (Coulter EPICS XL3, Miami, FL, U.S.A.). The content of intracellular IDA/DNR was determined by flow cytometry using the fluorescent properties of the drugs. DNR/IDA was excitated by an argon laser at 488 nm and the fluorescence signal was collected through a 515-535 nm (FL1 height), 565-585 nm (FL2 height) and 610-630 nm (FL3 height) bandpass filter set. The strongest emission was observed for the FL2 filter for IDA and FL3 filter for DNR. The instrument settings for FL2 and FL3 heights, forward scatter (FSC) and sideward scatter (SSC) were kept constant between two runs of the flow cytometer. The data were analysed using the SYSTEM II version 3.0 software (Beckman Coulter, Miami, FL, U.S.A.). Viable leukemic cells were gated based on FSC and SSC characteristics. The percentage of gated cells corresponded well with the percentage of viable cells determined morphologically by trypan blue exclusion. The intracellular drug content was determined by the mean fluorescence intensity of gated leukemic cells, and was expressed in arbitrary units (AU) on a log-scale. The FSC of gated leukemic cells was used as a relative measure of cell volume (FSC 3 ) in this study. The intracellular drug concentration (cDNR/cIDA) was obtained by dividing the intracellular DNR/IDA content by the relative cell volume (AU/FSC 3 ) [6] . The percentage of drug retention was calculated by dividing the drug-fluorescence retained in the cell after a period of efflux by the drug-fluorescence presVol. 49 Intracellular idarubicin and daunorubicin levelsent at the start of efflux (t = 0)´100%. The intracellular drug content, intracellular drug concentration or percentage of drug retention did not differ between bone marrow and peripheral blood samples. Therefore, those data were pooled for further analysis. In vitro drug resistance assay. The cytotoxicity of the drugs was measured by the MTT assay. The assay conditions were essentially the same as described previously [7] . Briefly, 80 ml of the cell suspension containing 2´10 6 vital cells/ml was incubated with each drug concentration (drug was added as a solution in 20 ml RPMI) in duplicate wells of a 96-well round-bottomed microtiter plate (Profilab, Warsaw, Poland). Six wells containing only cells in drug-free medium served as controls for cell survival, while six other wells containing only culture medium blanked the spectrophotometer. The outer wells of the plate were filled with RPMI-1640 only. Plates were then wrapped in cling film and incubated for 4 days (96 h) at 37°C in humidified air containing 5% CO 2 . After 4 days, 50 mg (10 ml of a 5 mg/ml solution) of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT, Serva, Heidelberg, Germany) was added to each well (final concentration 0.45 mg/ml); plates were shaken and incubated for another 6 h at 37°C. In such an exposure yellow MTT was reduced to purple formazan by viable, but not dead, cells. The formazan crystals were dissolved with 100 ml of acidified (0.04 M HCl) 2-isopropanolol (Sigma, St. Louis, MO, U.S.A.) and the quantity of the reduced product was measured by an ELISA EL-312 microplate spectrophotometer at 570 nm (Asys Hitech GmbH, Eugendorf, Austria). The absorbance (A 570 ) at this wavelength is linearly related to the number of viable cells [8] . Cytospin slides from control wells, stained with May-Grunwald-Giemsa, were used to determine the percentage of blasts after 96-h incubation. Samples with more than 70% leukemic cells in the control wells without drug after 4 days of culture and with an A 570 higher than 0.050 arbitrary units (adjusted for blank values) were considered suitable for evaluation. The leukemic cell survival was calculated by the equation: (A 570 drug well/mean A 570 control wells)´100%. The A 570 values of both control and tested wells were adjusted by the A 570 of blank wells. The LC 50 value, expressing the concentration of the drug that was lethal to 50% of the cells, was used as a measure of the in vitro drug cytotoxicity in each sample. PGP expression. PGP was analysed by flow cytometry. Mouse monoclonal antibodies anti-PGP-PE (cat. No. 340555, Becton Dickinson, San Jose, CA, U.S.A.), clone 15D3 transfected with the human multidrug resistance gene MDR1, were used. The amount of PE-labelling was detected by flow cytometry; red fluorescence was collected through a FL2 height bandpass filter set using log-mode amplification. Leukemic cells were gated based on FSC and SSC characteristics, and the fluorescence intensity of this population was expressed in arbitrary units on a log-scale. PGP expression was calculated as percentage of cells positive against isotype control of mouse anti-IgG1-PE. No difference between the fluorescence of bone marrow and peripheral blood samples was observed, therefore those data were pooled for further analysis.
Statistics. The non-parametric Wilcoxon matched-pairs signed ranks test was used to compare LC 50 values for PB and BM samples. The Mann-Whitney U test was used to compare accumulation and retention rates, as well as drug resistance, between groups. Correlations between parameters were calculated with Spearman's rho coefficient. All tests were used for two-tailed testing at a level of significance of 0.05.
RESULTS
The results (intracellular concentration, PGP expression, cytotoxicity) showed large interpatient variability. There was a big overlap of results inside each group of patients.
The uptake and efflux rates were higher for IDA, however, the differences were not significant. There were no statistical differences within any of the three groups of patients with respect to drug content during accumulation and retention (Fig. 2) . It seems that the higher rate of IDA transport was related to the lipophilic properties of the drugs rather than to the type of leukemia.
However, when the cell volume was used to calculate the intracellular drug concentration based on its intracellular content, differences were found. Intracellular concentration of each of the two drugs at each time point of both uptake and efflux (Table 1, Fig. 3 ) was significantly lower in relapsed ALL (group B) and AML (group C) samples than in initial ALL cells (group A). Those differences were related to the cell volumes larger in groups B and C than A (Table 2) .
There was no correlation between both drug accumulation and PGP expression at any time point during uptake. There was an inverse correlation between intracellular concentration of both drugs during efflux and PGP expression almost at each time point for all 61 patients (but not in any smaller group of patients with specific type of the disease) (Table 3). The in vitro cytotoxicity expressed as LC 50 was correlated with drug retention for IDA (p = 0.012 after 1 h and p = 0.024 after 2 h) but not DNR. The correlation between LC 50 and intracellular concentration during accumulation showed weak significance for both drugs (p < 0.05). The LC 50 values for DNR and IDA did not differ, whether in the whole group of patients (median 0.3594 mg/ml vs 0.3596 mg/ml) or in any subgroup, however, for each drug differences were observed between the three types of leukemia (Table 4) .
DISCUSSION
Anthracyclines are among the most commonly used anti-tumor drugs ever developed. The first identified anthracyclines, daunorubicin and doxorubicin, were isolated from pigment-producing Streptomyces species in the early 1960s [9] . The 4-demethoxy derivative of daunorubicin, idarubicin, is more effective than the parent compound in HL60 cell line [10] . Resistance to DNR has been shown to correlate with the prognosis of pediatric patients with ALL [11] . The present study tested whether decreased cellular uptake or increased cellular efflux of DNR and IDA may be responsible for cellular DNR/IDA resistance in childhood ALL and AML. The Cells were incubated with each drug at of 10 mg/ml. The intracellular drug content at each time point is given as the percentage of respective value at the end (accumulation phase) or at the beginning of the experiment (retention phase).
A B intracellular anthracycline levels may be lowered by efflux-mediating proteins, such as PGP, MRP and MVP/LRP [6, 12] , but it is thought that the role of these proteins in childhood leukemia is limited [13] . Previously, it has been shown that the transport rate depends on the hydrophobicity of the drug: more lipophilic anthracyclines such as IDA enter the cell faster compared with the less hydrophobic DNR [14] . We observed that in childhood leukemic cells, IDA is not only accumulated faster than DNR, but it is also faster sequestered out of the cell. This may have an impact on the higher IDA cytotoxicity. The accumulation rates for both drugs were inversely correlated with LC 50 values, reflecting drug sensitivity. On the other hand, faster IDA efflux could be related to the cellular resistance to this drug. Another important observation of the study is that while there were no differences in the intracellular content of IDA/DNR between the types of leukemia, there were significant differences in drug concentration. Larger cells were more resistant to either anthracycline. When the intracellular DNR content was corrected for cell volume, the intracellular DNR/IDA concentration inversely correlated with DNR/IDA resistance, both when the accumulation and retention of the drug were studied. These data show that not the decreased intracellular content but rather the decreased intracellular concentration may be an important mechanism of resistance which plays a role in the cytotoxic effect of both anthracyclines in childhood leukemia. Those observations, together with earlier results [6] , allowed us to draw more general conclusions. The highest concentration of each drug was in iALL, in correlation with the lowest drug resistance We frequently observed that after 3 h of accumulation most cells were killed by IDA at a concentration of 10 mg/ml.
In conclusion, while the intracellular content of both anthracyclines was similar during uptake and efflux in all groups of patients, the intracellular concentration of the drugs was significantly decreased in AML and relapsed ALL children. This possibly indicates an important drug resistance mechanism in childhood acute leukemia. Retention of both drugs weakly correlated with PGP expression and IDA, but not DNR, cytotoxicity. These observations suggest higher IDA cytotoxicity, possibly decreased by the presence of PGP. These results might have a practical impact on the rational design of new chemotherapy protocols. On the other hand, anthracycline accumulation can possibly be decreased also due Vol. 49 Intracellular idarubicin and daunorubicin levels 105 
